How Analysts Feel About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo
Investors sentiment decreased to 1.13 in Q2 2019. Its down 0.20, from 1.33 in 2019Q1. It is negative, as 31 investors sold BioMarin Pharmaceutical Inc. shares while 128 reduced holdings. 57 funds opened positions while 122 raised stakes. 172.04 million shares or 22.86% less from 223.01 million shares in 2019Q1 were reported.
Toth Fincl Advisory Corp owns 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 300 shares. Ellington Management Grp Incorporated Limited Liability Corp has invested 0.09% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Amalgamated State Bank stated it has 21,311 shares. Comm Retail Bank owns 7,431 shares. Alliancebernstein Ltd Partnership reported 106,969 shares. Dimensional Fund Advisors L P accumulated 339,024 shares. Charles Schwab Investment Mngmt invested in 0.02% or 467,810 shares. Sands Capital Ltd invested 1.46% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 11,633 are owned by Prelude Cap Mngmt Limited Com. Vanguard Group Inc reported 15.96 million shares or 0.05% of all its holdings. Nuveen Asset Management Ltd Limited Liability Company stated it has 3.01 million shares or 0.1% of all its holdings. Marshall Wace Ltd Liability Partnership accumulated 0.2% or 282,112 shares. Korea Inv reported 0.01% stake. Stifel Finance Corp reported 101,107 shares. Prudential Fincl Inc holds 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 102,010 shares.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 2 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioMarin Pharmaceutical has $12800 highest and $110 lowest target. $119’s average target is 63.80% above currents $72.65 stock price. BioMarin Pharmaceutical had 3 analyst reports since March 22, 2019 according to SRatingsIntel. Raymond James maintained the stock with “Outperform” rating in Tuesday, April 9 report. Wedbush maintained the stock with “Outperform” rating in Friday, April 26 report. Below is a list of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) latest ratings and price target changes.

26/04/2019 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $127.0000 New Target: $128.0000 Maintain
09/04/2019 Broker: Raymond James Rating: Outperform New Target: $110 Maintain
22/03/2019 Broker: BidaskScore Rating: Sell Downgrade

The stock decreased 0.21% or $0.15 during the last trading session, reaching $72.65. About 966,431 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 20.19% since September 13, 2018 and is downtrending. It has underperformed by 20.19% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $13.04 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Nasdaq.com which released: “Notable Friday Option Activity: BIIB, BMRN, EL – Nasdaq” on August 16, 2019, also Finance.Yahoo.com with their article: “Read This Before Buying BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares – Yahoo Finance” published on May 10, 2019, Seekingalpha.com published: “BioMarin Pharmaceutical EPS misses by $0.09, misses on revenue – Seeking Alpha” on August 01, 2019. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: Mallinkckrodt’s Terlipressin, Deciphera Offering, Sellas Reboots On Earnings – Benzinga” published on August 15, 2019 as well as Nasdaq.com‘s news article titled: “BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound? – Nasdaq” with publication date: August 31, 2019.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.